10.01.2017 23:06:00
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
NEW YORK, Jan. 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether DaVita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On January 6, 2017, the Wall Street Journal reported that DaVita had received subpoenas from federal prosecutors seeking "the production of information related to charitable premium assistance" in connection with DaVita's ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
On this news, DaVita stock fell $2.41, or 3.66%, to close at $63.38 on January 9, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-davita-inc---dva-300389015.html
SOURCE Pomerantz LLP
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DaVita HealthCare Partners Incmehr Nachrichten
14.02.25 |
NYSE-Handel: S&P 500 klettert (finanzen.at) | |
14.02.25 |
S&P 500-Handel aktuell: S&P 500 in der Gewinnzone (finanzen.at) | |
14.02.25 |
Zuversicht in New York: S&P 500 beginnt Sitzung mit Gewinnen (finanzen.at) | |
14.02.25 |
AKTIE IM FOKUS 2: FMC schwach - Davita überzeugt nicht, Hohe Sterblichkeit (dpa-AFX) | |
12.02.25 |
Ausblick: DaVita HealthCare Partners legt Quartalsergebnis vor (finanzen.net) | |
10.02.25 |
S&P 500-Papier DaVita HealthCare Partners-Aktie: So viel Gewinn hätte eine DaVita HealthCare Partners-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
03.02.25 |
S&P 500-Papier DaVita HealthCare Partners-Aktie: So viel Gewinn hätte ein Investment in DaVita HealthCare Partners von vor einem Jahr abgeworfen (finanzen.at) | |
27.01.25 |
S&P 500-Papier DaVita HealthCare Partners-Aktie: So viel hätten Anleger an einem DaVita HealthCare Partners-Investment von vor 10 Jahren verdient (finanzen.at) |
Analysen zu DaVita HealthCare Partners Incmehr Analysen
Aktien in diesem Artikel
DaVita HealthCare Partners Inc | 148,30 | -12,46% |
|